• Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.

  Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J.
  Sci Transl Med. 2022 Mar 16. 636(14).

• Photon Counting CT and Radiomic Analysis Enables Differentiation of Tumors Based on Lymphocyte Burden.

  Allphin AJ, Mowery YM, Lafata KJ, Clark DP, Bassil AM, Castillo R, Odhiambo D, Holbrook MD, Ghaghada KB, Badea CT.
  Tomography. 2022 Mar 10. 2(8).

• Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.

  Chakraborty S, Gonzalez JC, Sievers BL, Mallajosyula V, Chakraborty S, Dubey M, Ashraf U, Cheng BY, Kathale N, Tran KQT, Scallan C, Sinnott A, Cassidy A, Chen ST, Gelbart T, Gao F, Golan Y, Ji X, Kim-Schulze S, Prahl M, Gaw SL, Gnjatic S, Marron TU, Merad M, Arunachalam PS, Boyd SD, Davis MM, Holubar M, Khosla C, Maecker HT, Maldonado Y, Mellins ED, Nadeau KC, Pulendran B, Singh U, Subramanian A, Utz PJ, Sherwood R, Zhang S, Jagannathan P, Tan GS, Wang TT.
  Sci Transl Med. 2022 Mar 09. 635(14).

• Developmentally distinct CD4⁺ T_reg lineages shape the CD8⁺ T cell response to acute Listeria infection.

  Dolina JS, Lee J, Moore EL, Hope JL, Gracias DT, Matsutani T, Chawla A, Greenbaum JA, Linden J, Schoenberger SP.
  Proc Natl Acad Sci U S A. 2022 Mar 08. 10(119).

• Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

  Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M.
  Blood. 2022 Mar 03. 9(139).

• Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection.

  Heft Neal ME, Smith JD, Birkeland AC, Haring CT, Chinn SB, Shuman AG, Casper KA, Malloy KM, Stucken CL, Mclean SA, Rosko AJ, Mierzwa ML, Shah J, Schonewolf C, Swiecicki PL, Worden FP, Wolf GT, Bradford CR, Prince MEP, Brenner JC, Spector ME.
  Otolaryngol Head Neck Surg. 2022 Mar. 3(166).

• Practical and robust test for comparing binomial proportions in the randomized phase II setting.

  Attwood K, Park S, Hutson AD.
  Pharm Stat. 2022 Mar. 2(21).

• MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.

  Luan Z, Morimoto Y, Fushimi A, Yamashita N, Suo W, Bhattacharya A, Hagiwara M, Jin C, Kufe D.
  Carcinogenesis. 2022 Feb 11. 1(43).

• IKKα-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines.

  Song NY, Li X, Ma B, Willette-Brown J, Zhu F, Jiang C, Su L, Shetty J, Zhao Y, Shi G, Banerjee S, Wu X, Tran B, Nussinov R, Karin M, Hu Y.
  Proc Natl Acad Sci U S A. 2022 Feb 08. 6(119).

• Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy.

  Franiak-Pietryga I, Miyauchi S, Kim SS, Sanders PD, Sumner W, Zhang L, Mundt AJ, Califano JA, Sharabi AB.
  Int J Radiat Oncol Biol Phys. 2022 Feb 01. 2(112).

• Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.

  Hampton JD, Peterson EJ, Katner SJ, Turner TH, Alzubi MA, Harrell JC, Dozmorov MG, Turner JBM, Gigliotti PJ, Kraskauskiene V, Shende M, Idowu MO, Puchalapalli M, Hu B, Litovchick L, Katsuta E, Takabe K, Farrell NP, Koblinski JE.
  Mol Cancer Ther. 2022 Feb. 2(21).

• TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures.

  Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR.
  Immunity. 2022 Jan 11. 1(55).

• Regulation of antitumor immunity by inflammation-induced epigenetic alterations.

  Karin M, Shalapour S.
  Cell Mol Immunol. 2022 Jan. 1(19).

• Short-course neoadjuvant in situ vaccination for murine melanoma.

  Aiken TJ, Komjathy D, Rodriguez M, Stuckwisch A, Feils A, Subbotin V, Birstler J, Gillies SD, Rakhmilevich AL, Erbe AK, Sondel PM.
  J Immunother Cancer. 2022 Jan. 1(10).

• Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.

  Zhou L, Zeng Z, Egloff AM, Zhang F, Guo F, Campbell KM, Du P, Fu J, Zolkind P, Ma X, Zhang Z, Zhang Y, Wang X, Gu S, Riley R, Nakahori Y, Keegan J, Haddad R, Schoenfeld JD, Griffith O, Manguso RT, Lederer JA, Liu XS, Uppaluri R.
  J Immunother Cancer. 2022 Jan. 1(10).

• Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling.

  Makino K, Long MD, Kajihara R, Matsueda S, Oba T, Kanehira K, Liu S, Ito F.
  J Immunother Cancer. 2022 Jan. 1(10).

• Case-cohort design in hematopoietic cell transplant studies.

  Cai J, Kim S.
  Bone Marrow Transplant. 2022 Jan. 1(57).

• Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.

  Saglam O, Cao B, Wang X, Toruner GA, Conejo-Garcia JR.
  PLoS One. 2022. 2(17).

• Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.

  Rangel R, Pickering CR, Sikora AG, Spiotto MT.
  Front Immunol. 2022. (13).

• Tcf-1 protects anti-tumor TCR-engineered CD8⁺ T-cells from GzmB mediated self-destruction.

  Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K.
  Cancer Immunol Immunother. 2022 Apr 23. ().

• Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.

  Faraji F, Ramirez SI, Anguiano Quiroz PY, Mendez-Molina AN, Gutkind JS.
  Cells. 2022 Apr 18. 8(11).

• Understanding Drug Sensitivity and Tackling Resistance in Cancer.

  Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD.
  Cancer Res. 2022 Apr 15. 8(82).

• CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.

  Bernareggi D, Xie Q, Prager BC, Yun J, Cruz LS, Pham TV, Kim W, Lee X, Coffey M, Zalfa C, Azmoon P, Zhu H, Tamayo P, Rich JN, Kaufman DS.
  Nat Commun. 2022 Apr 07. 1(13).

• Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma.

  Altorki NK, Borczuk AC, Harrison S, Groner LK, Bhinder B, Mittal V, Elemento O, McGraw TE.
  Cell Rep. 2022 Apr 05. 1(39).

• MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.

  Bhattacharya A, Fushimi A, Yamashita N, Hagiwara M, Morimoto Y, Rajabi H, Long MD, Abdulla M, Ahmad R, Street K, Liu S, Liu T, Kufe D.
  Mol Cancer Res. 2022 Apr 01. 4(20).

• Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs.

  Gilardi M, Saddawi-Konefka R, Wu VH, Lopez-Ramirez MA, Wang Z, Soto F, Ramms DJ, Proietto M, Mikulski Z, Miki H, Sharabi A, Kupor D, Rueda R, Hollern DP, Wang J, Gutkind JS.
  Mol Cancer Ther. 2022 Apr 01. 4(21).

• PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

  Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE, Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB.
  Nat Med. 2022 Apr. 4(28).

• UACA locus is associated with breast cancer chemoresistance and survival.

  Zhu Q, Schultz E, Long J, Roh JM, Valice E, Laurent CA, Radimer KH, Yan L, Ergas IJ, Davis W, Ranatunga D, Gandhi S, Kwan ML, Bao PP, Zheng W, Shu XO, Ambrosone C, Yao S, Kushi LH.
  NPJ Breast Cancer. 2022 Mar 23. 1(8).

• A programmable encapsulation system improves delivery of therapeutic bacteria in mice.

  Harimoto T, Hahn J, Chen YY, Im J, Zhang J, Hou N, Li F, Coker C, Gray K, Harr N, Chowdhury S, Pu K, Nimura C, Arpaia N, Leong KW, Danino T.
  Nat Biotechnol. 2022 Mar 17. ().

• Cell-surface tethered promiscuous biotinylators enable comparative small-scale surface proteomic analysis of human extracellular vesicles and cells.

  Kirkemo LL, Elledge SK, Yang J, Byrnes JR, Glasgow JE, Blelloch R, Wells JA.
  Elife. 2022 Mar 08. (11).

• Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.

  von Itzstein MS, Gonugunta AS, Sheffield T, Homsi J, Dowell JE, Koh AY, Raj P, Fattah F, Wang Y, Basava VS, Khan S, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Xie Y, Li QZ, Wakeland EK, Gerber DE.
  Cancers (Basel). 2022 Mar 04. 5(14).

• Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions.

  Koşaloğlu-Yalçın Z, Lee J, Greenbaum J, Schoenberger SP, Miller A, Kim YJ, Sette A, Nielsen M, Peters B.
  iScience. 2022 Feb 18. 2(25).

• The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.

  Meier JA, Savoldo B, Grover NS.
  J Pers Med. 2022 Feb 01. 2(12).

• Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis.

  Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL.
  Blood Adv. 2022 Jan 25. 2(6).

• Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.

  von Itzstein MS, Gonugunta AS, Wang Y, Sheffield T, Lu R, Ali S, Fattah FJ, Xie D, Cai J, Xie Y, Gerber DE.
  Cancer Immunol Immunother. 2022 Jan 24. ().

• Interleukin-12 as an in situ cancer vaccine component: a review.

  Cheng EM, Tsarovsky NW, Sondel PM, Rakhmilevich AL.
  Cancer Immunol Immunother. 2022 Jan 13. ().

• Shift of lung macrophage composition is associated with COVID-19 disease severity and recovery.

  Chen ST, Park MD, Del Valle DM, Buckup M, Tabachnikova A, Simons NW, Mouskas K, Lee B, Geanon D, D'Souza D, Dawson T, Marvin R, Nie K, Thompson RC, Zhao Z, LeBerichel J, Chang C, Jamal H, Chaddha U, Mathews K, Acquah S, Brown SA, Reiss M, Harkin T, Feldmann M, Powell CA, Hook JL, Kim-Schulze S, Rahman AH, Brown BD, Beckmann ND, Gnjatic S, Kenigsberg E, Charney AW, Merad M.
  bioRxiv. 2022 Jan 12. ().

• Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network.

  Akturk G, Parra ER, Gjini E, Lako A, Lee JJ, Neuberg D, Zhang J, Yao S, Laface I, Rogic A, Chen PH, Sanchez-Espiridion B, Valle DMD, Moravec R, Kinders R, Hudgens C, Wu C, Wistuba II, Thurin M, Hewitt SM, Rodig S, Gnjatic S, Tetzlaff MT.
  Clin Cancer Res. 2021 Sep 15. 18(27).

• Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.

  Tewari AK, Cheung ATM, Crowdis J, Conway JR, Camp SY, Wankowicz SA, Livitz DG, Park J, Lis RT, Bosma-Moody A, He MX, AlDubayan SH, Zhang Z, McKay RR, Leshchiner I, Brown M, Balk SP, Getz G, Taplin ME, Van Allen EM.
  Cell Rep. 2021 Sep 07. 10(36).

• Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay.

  Hsiehchen D, Espinoza M, Gerber DE, Beg MS.
  Cancer Biol Ther. 2021 Sep 02. 7-9(22).

• Radiation-activated secretory proteins of Scgb1a1 ⁺ club cells increase the efficacy of immune checkpoint blockade in lung cancer.

  Ban Y, Markowitz GJ, Zou Y, Ramchandani D, Kraynak J, Sheng J, Lee SB, Wong STC, Altorki NK, Gao D, Mittal V.
  Nat Cancer. 2021 Sep. 9(2).

• How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.

  Stultz J, Fong L.
  Prostate Cancer Prostatic Dis. 2021 Sep. 3(24).

• Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.

  Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A.
  Cancer Discov. 2021 Sep. 9(11).

• BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.

  Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, Reich TJ, Bhoj VG, Haines KM, Maus MV, Melenhorst JJ, Young RM, Jadlowsky JK, Marcucci KT, Bradner JE, Levine BL, Porter DL, Bushman FD, Kohli RM, June CH, Davis MM, Lacey SF, Vahedi G, Fraietta JA.
  J Clin Invest. 2021 Aug 16. 16(131).

• Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children.

  Beckmann ND, Comella PH, Cheng E, Lepow L, Beckmann AG, Tyler SR, Mouskas K, Simons NW, Hoffman GE, Francoeur NJ, Del Valle DM, Kang G, Do A, Moya E, Wilkins L, Le Berichel J, Chang C, Marvin R, Calorossi S, Lansky A, Walker L, Yi N, Yu A, Chung J, Hartnett M, Eaton M, Hatem S, Jamal H, Akyatan A, Tabachnikova A, Liharska LE, Cotter L, Fennessy B, Vaid A, Barturen G, Shah H, Wang YC, Sridhar SH, Soto J, Bose S, Madrid K, Ellis E, Merzier E, Vlachos K, Fishman N, Tin M, Smith M, Xie H, Patel M, Nie K, Argueta K, Harris J, Karekar N, Batchelor C, Lacunza J, Yishak M, Tuballes K, Scott I, Kumar A, Jaladanki S, Agashe C, Thompson R, Clark E, Losic B, Peters L, Roussos P, Zhu J, Wang W, Kasarskis A, Glicksberg BS, Nadkarni G, Bogunovic D, Elaiho C, Gangadharan S, Ofori-Amanfo G, Alesso-Carra K, Onel K, Wilson KM, Argmann C, Bunyavanich S, Alarcón-Riquelme ME, Marron TU, Rahman A, Kim-Schulze S, Gnjatic S, Gelb BD, Merad M, Sebra R, Schadt EE, Charney AW.
  Nat Commun. 2021 Aug 11. 1(12).

• Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival.

  Gillani R, Seong BKA, Crowdis J, Conway JR, Dharia NV, Alimohamed S, Haas BJ, Han K, Park J, Dietlein F, He MX, Imamovic A, Ma C, Bassik MC, Boehm JS, Vazquez F, Gusev A, Liu D, Janeway KA, McFarland JM, Stegmaier K, Van Allen EM.
  Cancer Res. 2021 Aug 01. 15(81).

• Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.

  Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A, Bergeron H, Chapman-Davis E, Cantillo E, Holcomb K, Blank SV, Liu Y, Thomas C, Christos PJ, Wright DN, Lipkin S, Offit K, Frey MK.
  Gynecol Oncol. 2021 Aug. 2(162).

• BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells.

  Seo H, González-Avalos E, Zhang W, Ramchandani P, Yang C, Lio CJ, Rao A, Hogan PG.
  Nat Immunol. 2021 Aug. 8(22).

• Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies.

  Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K.
  Gastroenterology. 2021 Aug. 2(161).

• Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice.

  Carlson PM, Mohan M, Patel RB, Birstler J, Nettenstrom L, Sheerar D, Fox K, Rodriguez M, Hoefges A, Hernandez R, Zahm C, Kim K, McNeel DG, Weichert J, Morris ZS, Sondel PM.
  J Immunol. 2021 Jul 15. 2(207).

• Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.

  Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS.
  Sci Transl Med. 2021 Jul 14. 602(13).

• MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.

  Hagiwara M, Fushimi A, Yamashita N, Bhattacharya A, Rajabi H, Long MD, Yasumizu Y, Oya M, Liu S, Kufe D.
  Oncogene. 2021 Jul. 30(40).

• A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.

  Kim E, Weisel FJ, Balmert SC, Khan MS, Huang S, Erdos G, Kenniston TW, Carey CD, Joachim SM, Conter LJ, Weisel NM, Okba NMA, Haagmans BL, Percivalle E, Cassaniti I, Baldanti F, Korkmaz E, Shlomchik MJ, Falo LD, Gambotto A.
  Eur J Immunol. 2021 Jul. 7(51).

• A robust permutation test for the concordance correlation coefficient.

  Hutson AD, Yu H.
  Pharm Stat. 2021 Jul. 4(20).

• Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.

  Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ.
  Blood. 2021 Jun 10. 23(137).

• Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers.

  Paczesny S, Pasquini MC, Pavletic SZ, Agarwal A, Spellman S, Kean L, Bernatchez C, Gust J, Staedtke V, Perales MA.
  Blood Adv. 2021 Jun 08. 11(5).

• Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.

  Clark PA, Sriramaneni RN, Bates AM, Jin WJ, Jagodinsky JC, Hernandez R, Le T, Jeffery JJ, Marsh IR, Grudzinski JJ, Aluicio-Sarduy E, Barnhart TE, Anderson BR, Chakravarty I, Arthur IS, Kim K, Engle JW, Bednarz BP, Weichert JP, Morris ZS.
  Radiat Res. 2021 Jun 01. 6(195).

• Dynamic patterns of DNA methylation in the normal prostate epithelial differentiation program are targets of aberrant methylation in prostate cancer.

  Long MD, Dhiman VK, Affronti HC, Hu Q, Liu S, Smiraglia DJ.
  Sci Rep. 2021 Jun 01. 1(11).

• Commentary: Can machine learning reduce readmissions after esophagectomy? A consummation devoutly to be wished.

  Altorki N, Sedrakyan A.
  J Thorac Cardiovasc Surg. 2021 Jun. 6(161).

• CD8⁺ T cell immunity blocks the metastasis of carcinogen-exposed breast cancer.

  Li K, Li T, Feng Z, Huang M, Wei L, Yan Z, Long M, Hu Q, Wang J, Liu S, Sgroi DC, Demehri S.
  Sci Adv. 2021 Jun. 25(7).

• Integrative sequencing discovers an ATF1-motif enriched molecular signature that differentiates hyalinizing clear cell carcinoma from mucoepidemoid carcinoma.

  Heft Neal ME, Gensterblum-Miller E, Bhangale AD, Kulkarni A, Zhai J, Smith J, Brummel C, Foltin SK, Thomas D, Jiang H, McHugh JB, Brenner JC.
  Oral Oncol. 2021 Jun. (117).

• Genetic and biological hallmarks of colorectal cancer.

  Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA.
  Genes Dev. 2021 Jun. 11-12(35).

• Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.

  Pieper AA, Rakhmilevich AL, Spiegelman DV, Patel RB, Birstler J, Jin WJ, Carlson PM, Charych DH, Hank JA, Erbe AK, Overwijk WW, Morris ZS, Sondel PM.
  J Immunother Cancer. 2021 Jun. 6(9).
  
  Clinical Trial

• Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.

  Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE.
  J Immunother Cancer. 2021 Jun. 6(9).

• Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms.

  Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydillo T, Parigi TL, Ladinsky MS, Ramos I, Dunleavy K, Lee B, Dixon RE, Chen ST, Martinez-Delgado G, Nagula S, Bruce EA, Ko HM, Glicksberg BS, Nadkarni G, Pujadas E, Reidy J, Naymagon S, Grinspan A, Ahmad J, Tankelevich M, Bram Y, Gordon R, Sharma K, Houldsworth J, Britton GJ, Chen-Liaw A, Spindler MP, Plitt T, Wang P, Cerutti A, Faith JJ, Colombel JF, Kenigsberg E, Argmann C, Merad M, Gnjatic S, Harpaz N, Danese S, Cordon-Cardo C, Rahman A, Schwartz RE, Kumta NA, Aghemo A, Bjorkman PJ, Petralia F, van Bakel H, Garcia-Sastre A, Mehandru S.
  Gastroenterology. 2021 Jun. 7(160).

• Why are immune adverse events so common with checkpoint inhibitor therapy?

  Lyubchenko T, Leung DYM, Goleva E.
  Ann Allergy Asthma Immunol. 2021 Jun. 6(126).

• Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.

  Goleva E, Lyubchenko T, Kraehenbuehl L, Lacouture ME, Leung DYM, Kern JA.
  Ann Allergy Asthma Immunol. 2021 Jun. 6(126).

• Immune-related cutaneous adverse events due to checkpoint inhibitors.

  Wang E, Kraehenbuehl L, Ketosugbo K, Kern JA, Lacouture ME, Leung DYM.
  Ann Allergy Asthma Immunol. 2021 Jun. 6(126).

• Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.

  Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Laetsch TW, Wiener L, Gardner RA, Nussenblatt V, Hill JA, Curran KJ, Olson TS, Annesley C, Wang HW, Khan J, Pasquini MC, Duncan CN, Grupp SA, Pulsipher MA, Shah NN.
  Nat Rev Clin Oncol. 2021 Jun. 6(18).

• Melanoma models for the next generation of therapies.

  Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Burd CE, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G.
  Cancer Cell. 2021 May 10. 5(39).

• Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.

  Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM.
  Cancer Cell. 2021 May 10. 5(39).

• A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.

  Monjazeb AM, Giobbie-Hurder A, Lako A, Thrash EM, Brennick RC, Kao KZ, Manuszak C, Gentzler RD, Tesfaye A, Jabbour SK, Alese OB, Rahma OE, Cleary JM, Sharon E, Mamon HJ, Cho M, Streicher H, Chen HX, Ahmed MM, Mariño-Enríquez A, Kim-Schulze S, Gnjatic S, Maverakis E, Marusina AI, Merleev AA, Severgnini M, Pfaff KL, Lindsay J, Weirather JL, Ranasinghe S, Spektor A, Rodig SJ, Hodi SF, Schoenfeld JD.
  Clin Cancer Res. 2021 May 01. 9(27).

• Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.

  Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L.
  J Immunother Cancer. 2021 May. 5(9).
  
  Clinical Trial

• Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?

  Hou J, Karin M, Sun B.
  Nat Rev Clin Oncol. 2021 May. 5(18).

• ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer.

  Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, Poirier JT, Peng DH, Bulatovic M, Mukhopadhyay S, Silver H, Papadopoulos E, Pyon V, Thakurdin C, Han H, Li F, Li S, Ding H, Hu H, Pan Y, Weerasekara V, Jiang B, Wang ES, Ahearn I, Philips M, Papagiannakopoulos T, Tsirigos A, Rothenberg E, Gainor J, Freeman GJ, Rudin CM, Gray NS, Hammerman PS, Pagano M, Heymach JV, Perou CM, Bardeesy N, Wong KK.
  Nat Cancer. 2021 May. 5(2).

• Prolonged activation of innate immune pathways by a polyvalent STING agonist.

  Li S, Luo M, Wang Z, Feng Q, Wilhelm J, Wang X, Li W, Wang J, Cholka A, Fu YX, Sumer BD, Yu H, Gao J.
  Nat Biomed Eng. 2021 May. 5(5).

• SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.

  Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, Cho J, Briones JD, Duecker JM, Goretsky YE, Dannenfelser R, Cardarelli L, Troyanskaya O, Sidhu SS, Roybal KT, Okada H, Lim WA.
  Sci Transl Med. 2021 Apr 28. 591(13).

• Current Concepts and Advances in Graft-Versus-Host Disease Immunology.

  Hill GR, Betts BC, Tkachev V, Kean LS, Blazar BR.
  Annu Rev Immunol. 2021 Apr 26. (39).

• Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.

  Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A, Molinolo AA, Duvvuri U, Grandis JR, Califano JA, Cohen EEW, Gutkind JS.
  Nat Commun. 2021 Apr 22. 1(12).

• The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design.

  Saxton RA, Henneberg LT, Calafiore M, Su L, Jude KM, Hanash AM, Garcia KC.
  Immunity. 2021 Apr 13. 4(54).

• TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections.

  Yum S, Li M, Fang Y, Chen ZJ.
  Proc Natl Acad Sci U S A. 2021 Apr 06. 14(118).

• Artificial Intelligence in Cancer Research and Precision Medicine.

  Bhinder B, Gilvary C, Madhukar NS, Elemento O.
  Cancer Discov. 2021 Apr. 4(11).

• Frontiers in cancer immunotherapy-a symposium report.

  Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL.
  Ann N Y Acad Sci. 2021 Apr. 1(1489).

• Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.

  Mithraprabhu S, Kalff A, Gartlan KH, Savvidou I, Khong T, Ramachandran M, Cooke RE, Bowen K, Hill GR, Reynolds J, Spencer A.
  Br J Haematol. 2021 Apr. 1(193).

• The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFN-β pathway.

  Takahashi M, Lio CJ, Campeau A, Steger M, Ay F, Mann M, Gonzalez DJ, Jain M, Sharma S.
  Nat Immunol. 2021 Apr. 4(22).

• Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model.

  Carlson PM, Mohan M, Rodriguez M, Subbotin V, Sun CX, Patel RB, Birstler J, Hank JA, Rakhmilevich AL, Morris ZS, Erbe AK, Sondel PM.
  J Immunother Cancer. 2021 Apr. 4(9).

• Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.

  Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK.
  Nat Rev Clin Oncol. 2021 Apr. 4(18).

• RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets.

  Pan Y, Kadash-Edmondson KE, Wang R, Phillips J, Liu S, Ribas A, Aplenc R, Witte ON, Xing Y.
  Trends Pharmacol Sci. 2021 Apr. 4(42).

• Phosphorylation and chromatin tethering prevent cGAS activation during mitosis.

  Li T, Huang T, Du M, Chen X, Du F, Ren J, Chen ZJ.
  Science. 2021 Mar 19. 6535(371).

• Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10.

  Saxton RA, Tsutsumi N, Su LL, Abhiraman GC, Mohan K, Henneberg LT, Aduri NG, Gati C, Garcia KC.
  Science. 2021 Mar 19. 6535(371).

• Functional Analysis of Immune Signature Genes in Th1* Memory Cells Links ISOC1 and Pyrimidine Metabolism to IFN-γ and IL-17 Production.

  Kushnareva Y, Mathews IT, Andreyev AY, Altay G, Lindestam Arlehamn CS, Pandurangan V, Nilsson R, Jain M, Sette A, Peters B, Sharma S.
  J Immunol. 2021 Mar 15. 6(206).

• T cell circuits that sense antigen density with an ultrasensitive threshold.

  Hernandez-Lopez RA, Yu W, Cabral KA, Creasey OA, Lopez Pazmino MDP, Tonai Y, De Guzman A, Mäkelä A, Saksela K, Gartner ZJ, Lim WA.
  Science. 2021 Mar 12. 6534(371).

• The functions of autophagy at the tumour-immune interface.

  Luo X, Qiu Y, Dinesh P, Gong W, Jiang L, Feng X, Li J, Jiang Y, Lei YL, Chen Q.
  J Cell Mol Med. 2021 Mar. 5(25).

• IgA transcytosis and antigen recognition govern ovarian cancer immunity.

  Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR.
  Nature. 2021 Mar. 7850(591).

• Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy.

  Lorkowski ME, Atukorale PU, Ghaghada KB, Karathanasis E.
  Adv Healthc Mater. 2021 Mar. 5(10).

• Epigenetic modulation of immunotherapy and implications in head and neck cancer.

  Zhou L, Xu N, Shibata H, Saloura V, Uppaluri R.
  Cancer Metastasis Rev. 2021 Mar. 1(40).

• Transcriptional mediators of treatment resistance in lethal prostate cancer.

  He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z, Tewari AK, Liu D, Camp SY, Vokes NI, Salari K, Park J, Vigneau S, Fong L, Russo JW, Yuan X, Balk SP, Beltran H, Rozenblatt-Rosen O, Regev A, Rotem A, Taplin ME, Van Allen EM.
  Nat Med. 2021 Mar. 3(27).

• How old is too old for a transplant?

  Weisdorf D.
  Best Pract Res Clin Haematol. 2021 Mar. 1(34).

• Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.

  Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S.
  Proc Natl Acad Sci U S A. 2021 Feb 23. 8(118).
  
  Data Model

• MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells.

  Hagiwara M, Yasumizu Y, Yamashita N, Rajabi H, Fushimi A, Long MD, Li W, Bhattacharya A, Ahmad R, Oya M, Liu S, Kufe D.
  Cancer Res. 2021 Feb 15. 4(81).
  
  Data

• Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19⁺ Tumors.

  Grover NS, Tschernia N, Dotti G, Savoldo B.
  J Clin Oncol. 2021 Feb 10. 5(39).

• Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA.

  Dermody SM, Haring CT, Bhambhani C, Tewari M, Brenner JC, Swiecicki PL.
  Curr Treat Options Oncol. 2021 Feb 08. 3(22).

• The neglected brothers come of age: B cells and cancer.

  Shalapour S, Karin M.
  Semin Immunol. 2021 Feb. (52).

• Comparison of HLA ligand elution data and binding predictions reveals varying prediction performance for the multiple motifs recognized by HLA-DQ2.5.

  Koşaloğlu-Yalçın Z, Sidney J, Chronister W, Peters B, Sette A.
  Immunology. 2021 Feb. 2(162).

• Tumor-Targeted Inhibition of Monocarboxylate Transporter 1 Improves T-Cell Immunotherapy of Solid Tumors.

  Huang T, Feng Q, Wang Z, Li W, Sun Z, Wilhelm J, Huang G, Vo T, Sumer BD, Gao J.
  Adv Healthc Mater. 2021 Feb. 4(10).

• DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation.

  Huang X, Williams JZ, Chang R, Li Z, Burnett CE, Hernandez-Lopez R, Setiady I, Gai E, Patterson DM, Yu W, Roybal KT, Lim WA, Desai TA.
  Nat Nanotechnol. 2021 Feb. 2(16).

• HLA-A^∗02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses.

  Nesterenko PA, McLaughlin J, Tsai BL, Burton Sojo G, Cheng D, Zhao D, Mao Z, Bangayan NJ, Obusan MB, Su Y, Ng RH, Chour W, Xie J, Li YR, Lee D, Noguchi M, Carmona C, Phillips JW, Kim JT, Yang L, Heath JR, Boutros PC, Witte ON.
  Cell Rep. 2021 Dec 28. 13(37).

• A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia.

  Zhang Q, Hresko ME, Picton LK, Su L, Hollander MJ, Nunez-Cruz S, Zhang Z, Assenmacher CA, Sockolosky JT, Garcia KC, Milone MC.
  Sci Transl Med. 2021 Dec 22. 625(13).

• The onset of circulation triggers a metabolic switch required for endothelial to hematopoietic transition.

  Azzoni E, Frontera V, Anselmi G, Rode C, James C, Deltcheva EM, Demian AS, Brown J, Barone C, Patelli A, Harman JR, Nicholls M, Conway SJ, Morrissey E, Jacobsen SEW, Sparrow DB, Harris AL, Enver T, de Bruijn MFTR.
  Cell Rep. 2021 Dec 14. 11(37).

• Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

  Long MD, Jacobi JJ, Singh PK, Llimos G, Wani SA, Rowsam AM, Rosario SR, Hoogstraat M, Linder S, Kirk J, Affronti HC, Bergman A, Zwart W, Campbell MJ, Smiraglia DJ.
  Cell Rep. 2021 Dec 14. 11(37).

• CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease.

  Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Meshgin N, Papachristoforou E, Argemi J, Mendes BG, Wang Y, Su H, Sun W, Llorente C, Hendrikx T, Liu X, Hosseini M, Kisseleva T, Brenner DA, Bataller R, Ramachandran P, Karin M, Fu W, Schnabl B.
  Nat Commun. 2021 Dec 09. 1(12).

• Pan-cancer analysis reveals molecular patterns associated with age.

  Shah Y, Verma A, Marderstein AR, White J, Bhinder B, Garcia Medina JS, Elemento O.
  Cell Rep. 2021 Dec 07. 10(37).

• Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition.

  Akama-Garren EH, Morris ZS, Sikora AG, Weichselbaum R, Schoenfeld JD.
  Int J Radiat Oncol Biol Phys. 2021 Dec 01. 5(111).

• Humoral and cellular correlates of a novel immune-related adverse event and its treatment.

  Gonugunta AS, von Itzstein MS, Mu-Mosley H, Fattah F, Farrar JD, Mobely A, Rashdan S, Lai S, Bhai SF, Bermas BL, Karp D, Li QZ, Wakeland EK, Gerber DE.
  J Immunother Cancer. 2021 Dec. 12(9).

• Dermatologic infections in cancer patients treated with checkpoint inhibitors.

  Do MH, Barrios DM, Phillips GS, Postow MA, Warner AB, Rosenberg JE, Noor SJ, Markova A, Lacouture ME.
  J Am Acad Dermatol. 2021 Dec. 6(85).

• Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells.

  Liu L, Chen J, Bae J, Li H, Sun Z, Moore C, Hsu E, Han C, Qiao J, Fu YX.
  Nat Biomed Eng. 2021 Nov. 11(5).

• Obstacles and opportunities in a forward vision for cancer nanomedicine.

  de Lázaro I, Mooney DJ.
  Nat Mater. 2021 Nov. 11(20).

• Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy.

  Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, Xu Y, Nam J, Xu J, Shi X, Wei L, Lei YL, Moon JJ.
  Nat Nanotechnol. 2021 Nov. 11(16).

• BETting on BRD4 inhibition to combat adaptive resistance to CAR T cell therapy in glioblastoma.

  Hopkins CR, Fraietta JA.
  Mol Ther. 2021 Oct 06. 10(29).

• SearcHPV: A novel approach to identify and assemble human papillomavirus-host genomic integration events in cancer.

  Pinatti LM, Gu W, Wang Y, Elhossiny A, Bhangale AD, Brummel CV, Carey TE, Mills RE, Brenner JC.
  Cancer. 2021 Oct 01. 19(127).

• Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.

  Gebert J, Gelincik O, Oezcan-Wahlbrink M, Marshall JD, Hernandez-Sanchez A, Urban K, Long M, Cortes E, Tosti E, Katzenmaier EM, Song Y, Elsaadi A, Deng N, Vilar E, Fuchs V, Nelius N, Yuan YP, Ahadova A, Sei S, Shoemaker RH, Umar A, Wei L, Liu S, Bork P, Edelmann W, von Knebel Doeberitz M, Lipkin SM, Kloor M.
  Gastroenterology. 2021 Oct. 4(161).

• CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer.

  Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi K.
  J Immunother Cancer. 2021 Oct. 10(9).

• KIT^low Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor.

  Banerjee S, Yoon H, Ting S, Tang CM, Yebra M, Wenzel AT, Yeerna H, Mesirov JP, Wechsler-Reya RJ, Tamayo P, Sicklick JK.
  Mol Cancer Ther. 2021 Oct. 10(20).

• Biologically informed deep neural network for prostate cancer discovery.

  Elmarakeby HA, Hwang J, Arafeh R, Crowdis J, Gang S, Liu D, AlDubayan SH, Salari K, Kregel S, Richter C, Arnoff TE, Park J, Hahn WC, Van Allen EM.
  Nature. 2021 Oct. 7880(598).

• Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes.

  Aggarwala V, Mogno I, Li Z, Yang C, Britton GJ, Chen-Liaw A, Mitcham J, Bongers G, Gevers D, Clemente JC, Colombel JF, Grinspan A, Faith J.
  Nat Microbiol. 2021 Oct. 10(6).

• Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.

  Luo J, Beattie JA, Fuentes P, Rizvi H, Egger JV, Kern JA, Leung DYM, Lacouture ME, Kris MG, Gambarin M, Santomasso BD, Faleck DM, Hellmann MD.
  J Thorac Oncol. 2021 Oct. 10(16).

• RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization.

  Alqassim EY, Sharma S, Khan ANMNH, Emmons TR, Cortes Gomez E, Alahmari A, Singel KL, Mark J, Davidson BA, Robert McGray AJ, Liu Q, Lichty BD, Moysich KB, Wang J, Odunsi K, Segal BH, Baysal BE.
  Commun Biol. 2021 Jan 22. 1(4).

• Droplet-based mRNA sequencing of fixed and permeabilized cells by CLInt-seq allows for antigen-specific TCR cloning.

  Nesterenko PA, McLaughlin J, Cheng D, Bangayan NJ, Burton Sojo G, Seet CS, Qin Y, Mao Z, Obusan MB, Phillips JW, Witte ON.
  Proc Natl Acad Sci U S A. 2021 Jan 19. 3(118).
  
  Data

• Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas.

  Keenan BP, Fong L.
  Cancer Discov. 2021 Jan. 1(11).

• NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

  Sanchez CE, Dowlati EP, Geiger AE, Chaudhry K, Tovar MA, Bollard CM, Cruz CRY.
  Transplant Cell Ther. 2021 Jan. 1(27).

• Liver Cancer Immunity.

  Rizvi S, Wang J, El-Khoueiry AB.
  Hepatology. 2021 Jan. (73 Suppl 1).

• MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.

  Yamashita N, Long M, Fushimi A, Yamamoto M, Hata T, Hagiwara M, Bhattacharya A, Hu Q, Wong KK, Liu S, Kufe D.
  J Immunother Cancer. 2021 Jan. 1(9).
  
  Data

• Shining a light on metabolic vulnerabilities in non-small cell lung cancer.

  Dowling CM, Zhang H, Chonghaile TN, Wong KK.
  Biochim Biophys Acta Rev Cancer. 2021 Jan. 1(1875).

• The Radiobiology of Radiopharmaceuticals.

  Morris ZS, Wang AZ, Knox SJ.
  Semin Radiat Oncol. 2021 Jan. 1(31).

• Ultradeep sequencing differentiates patterns of skin clonal mutations associated with sun-exposure status and skin cancer burden.

  Wei L, Christensen SR, Fitzgerald ME, Graham J, Hutson ND, Zhang C, Huang Z, Hu Q, Zhan F, Xie J, Zhang J, Liu S, Remenyik E, Gellen E, Colegio OR, Bax M, Xu J, Lin H, Huss WJ, Foster BA, Paragh G.
  Sci Adv. 2021 Jan. 1(7).

• Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion.

  Gong W, Donnelly CR, Heath BR, Bellile E, Donnelly LA, Taner HF, Broses L, Brenner JC, Chinn SB, Ji RR, Wen H, Nör JE, Wang J, Wolf GT, Xie Y, Lei YL.
  Oncoimmunology. 2021. 1(10).

• Machine learning-assisted immune profiling stratifies peri-implantitis patients with unique microbial colonization and clinical outcomes.

  Wang CW, Hao Y, Di Gianfilippo R, Sugai J, Li J, Gong W, Kornman KS, Wang HL, Kamada N, Xie Y, Giannobile WV, Lei YL.
  Theranostics. 2021. 14(11).

• Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?

  Minnie SA, Hill GR.
  Front Immunol. 2021. (12).

• Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models.

  Pieper AA, Zangl LM, Speigelman DV, Feils AS, Hoefges A, Jagodinsky JC, Felder MA, Tsarovsky NW, Arthur IS, Brown RJ, Birstler J, Le T, Carlson PM, Bates AM, Hank JA, Rakhmilevich AL, Erbe AK, Sondel PM, Patel RB, Morris ZS.
  Front Immunol. 2021. (12).

• Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.

  Magee K, Marsh IR, Turek MM, Grudzinski J, Aluicio-Sarduy E, Engle JW, Kurzman ID, Zuleger CL, Oseid EA, Jaskowiak C, Albertini MR, Esbona K, Bednarz B, Sondel PM, Weichert JP, Morris ZS, Hernandez R, Vail DM.
  PLoS One. 2021. 8(16).

• Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer.

  Bates AM, Brown RJ, Pieper AA, Zangl LM, Arthur I, Carlson PM, Le T, Sosa GA, Clark PA, Sriramaneni RN, Kim K, Patel RB, Morris ZS.
  Front Oncol. 2021. (11).
  
  Clinical Trial

• The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community.

  Koşaloğlu-Yalçın Z, Blazeska N, Carter H, Nielsen M, Cohen E, Kufe D, Conejo-Garcia J, Robbins P, Schoenberger SP, Peters B, Sette A.
  Front Immunol. 2021. (12).

• A Nanoradiomics Approach for Differentiation of Tumors Based on Tumor-Associated Macrophage Burden.

  Starosolski Z, Courtney AN, Srivastava M, Guo L, Stupin I, Metelitsa LS, Annapragada A, Ghaghada KB.
  Contrast Media Mol Imaging. 2021. (2021).

• Integrating CD4⁺ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model.

  Shibata H, Xu N, Saito S, Zhou L, Ozgenc I, Webb J, Fu C, Zolkind P, Egloff AM, Uppaluri R.
  Oncoimmunology. 2021. 1(10).

• Inference for L-estimators of location using a bootstrap warping approach.

  Hutson AD.
  Commun Stat Simul Comput. 2021. 7(50).

• IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation.

  Amobi-McCloud A, Muthuswamy R, Battaglia S, Yu H, Liu T, Wang J, Putluri V, Singh PK, Qian F, Huang RY, Putluri N, Tsuji T, Lugade AA, Liu S, Odunsi K.
  Front Immunol. 2021. (12).

• A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.

  McGray AJR, Eppolito C, Miliotto A, Singel KL, Stephenson K, Lugade A, Segal BH, Keler T, Webster G, Lichty B, Kozbor D, Odunsi K.
  Cancer Immunol Immunother. 2021 Dec. 12(70).

• Image-based patient-specific flow simulations are consistent with stroke in pediatric cerebrovascular disease.

  Hossain SS, Starosolski Z, Sanders T, Johnson MJ, Wu MCH, Hsu MC, Milewicz DM, Annapragada A.
  Biomech Model Mechanobiol. 2021 Dec. 6(20).

• Quantitative chest CT combined with plasma cytokines predict outcomes in COVID-19 patients.

  Carbonell G, Del Valle DM, Gonzalez-Kozlova E, Marinelli B, Klein E, Homsi ME, Stocker D, Chung M, Bernheim A, Simons NW, Xiang J, Nirenberg S, Kovatch P, Lewis S, Merad M, Gnjatic S, Taouli B.
  medRxiv. 2021 Oct 14. ().

• Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.

  Ogunnaike EA, Valdivia A, Yazdimamaghani M, Leon E, Nandi S, Hudson H, Du H, Khagi S, Gu Z, Savoldo B, Ligler FS, Hingtgen S, Dotti G.
  Sci Adv. 2021 Oct 08. 41(7).

• Acute COVID-19 gene-expression profiles show multiple etiologies of long-term sequelae.

  Thompson RC, Simons NW, Wilkins L, Cheng E, Del Valle DM, Hoffman GE, Fennessy B, Mouskas K, Francoeur NJ, Johnson JS, Lepow L, Berichel JL, Chang C, Beckmann AG, Wang YC, Nie K, Zaki N, Tuballes K, Barcessat V, Cedillo MA, Huckins L, Roussos P, Marron TU, Glicksberg BS, Nadkarni G, Gonzalez-Kozlova E, Kim-Schulze S, Sebra R, Merad M, Gnjatic S, Schadt EE, Charney AW, Beckmann ND.
  medRxiv. 2021 Oct 05. ().

• Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology.

  Reardon B, Moore ND, Moore NS, Kofman E, AlDubayan SH, Cheung ATM, Conway J, Elmarakeby H, Imamovic A, Kamran SC, Keenan T, Keliher D, Konieczkowski DJ, Liu D, Mouw KW, Park J, Vokes NI, Dietlein F, Van Allen EM.
  Nat Cancer. 2021 Oct. 10(2).

• Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.

  Wustrack RL, Shao E, Sheridan J, Zimel M, Cho SJ, Horvai AE, Luong D, Kwek SS, Fong L, Okimoto RA.
  Cancer Immunol Immunother. 2021 Oct. 10(70).

• An Accelerated Life Model Analog for Discrete Survival and Count Data.

  Hutson AD.
  Comput Methods Programs Biomed. 2021 Oct. (210).

• Machine Learning Incorporating Host Factors for Predicting Survival in Head and Neck Squamous Cell Carcinoma Patients.

  Yu H, Ma SJ, Farrugia M, Iovoli AJ, Wooten KE, Gupta V, McSpadden RP, Kuriakose MA, Markiewicz MR, Chan JM, Hicks WL, Platek ME, Singh AK.
  Cancers (Basel). 2021 Sep 11. 18(13).

• Polyvalent design in the cGAS-STING pathway.

  Bennett ZT, Li S, Sumer BD, Gao J.
  Semin Immunol. 2021 Aug. (56).

• Esomeprazole enhances the effect of ionizing radiation to improve tumor control.

  Hebert KA, Jaramillo S, Yu W, Wang M, Veeramachaneni R, Sandulache VC, Sikora AG, Bonnen MD, Annapragada AV, Corry D, Kheradmand F, Pandita RK, Ludwig MS, Pandita TK, Huang S, Coarfa C, Grimm SL, Perera D, Miles G, Ghebre YT.
  Oncotarget. 2021 Jul 06. 14(12).

• Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.

  Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L.
  Cancer Immunol Immunother. 2021 Jul. 7(70).
  
  Clinical Trial

• Finding the optimal partner to pair with bispecific antibody therapy for multiple myeloma.

  Louvet C, Nadeem O, Smith EL.
  Blood Cancer Discov. 2021 Jul. 4(2).

• Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies.

  Zhang M, Hong JA, Kunst TF, Bond CD, Kenney CM, Warga CL, Yeray J, Lee MJ, Yuno A, Lee S, Miettinen M, Ripley RT, Hoang CD, Gnjatic S, Trepel JB, Schrump DS.
  Transl Lung Cancer Res. 2021 Jul. 7(10).

• A rigorous evaluation of optimal peptide targets for MS-based clinical diagnostics of Coronavirus Disease 2019 (COVID-19).

  Rajczewski AT, Mehta S, Nguyen DDA, Grüning B, Johnson JE, McGowan T, Griffin TJ, Jagtap PD.
  Clin Proteomics. 2021 May 10. 1(18).

• Towards artificial intelligence-driven pathology assessment for hematological malignancies.

  Elemento O.
  Blood Cancer Discov. 2021 May. 3(2).

• Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.

  Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A.
  J Cancer Prev. 2021 Mar 30. 1(26).

• Bioconductor toolchain for reproducible bioinformatics pipelines using Rcwl and RcwlPipelines.

  Hu Q, Hutson A, Liu S, Morgan M, Liu Q.
  Bioinformatics. 2021 Mar 27. ().

• Personalized cancer vaccination in head and neck cancer.

  Shibata H, Zhou L, Xu N, Egloff AM, Uppaluri R.
  Cancer Sci. 2021 Mar. 3(112).

• Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis.

  Yan BY, Wasilewski G, Lacouture ME, Barker CA.
  J Am Acad Dermatol. 2021 Mar. 3(84).

• Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.

  Osum SH, Watson AL, Largaespada DA.
  Int J Mol Sci. 2021 Feb 16. 4(22).

• MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

  Kufe DW.
  Carcinogenesis. 2020 Sep 24. 9(41).

• Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.

  Dannenfelser R, Allen GM, VanderSluis B, Koegel AK, Levinson S, Stark SR, Yao V, Tadych A, Troyanskaya OG, Lim WA.
  Cell Syst. 2020 Sep 23. 3(11).

• The Promise of Combining Radiation Therapy With Immunotherapy.

  Jagodinsky JC, Harari PM, Morris ZS.
  Int J Radiat Oncol Biol Phys. 2020 Sep 01. 1(108).

• Inhibition of LSD1 in MDS progenitors restores differentiation of CD141^Hi conventional dendritic cells.

  Srivastava P, Tzetzo SL, Gomez EC, Eng KH, Jani Sait SN, Kuechle JB, Singh PK, De Jong K, Wiatrowski KR, Peresie J, Dimitroff A, Lynch ML, Wang J, Abrams SI, Griffiths EA, Nemeth MJ.
  Leukemia. 2020 Sep. 9(34).

• BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.

  Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, Costich TL, Harro CM, Walrath J, Ming Q, Tcyganov E, Buras AL, Rigolizzo KE, Mandal G, Lajoie J, Ophir M, Tchou J, Marchion D, Luca VC, Bobrowicz P, McLaughlin B, Eskiocak U, Schmidt M, Cubillos-Ruiz JR, Rodriguez PC, Gabrilovich DI, Conejo-Garcia JR.
  Science. 2020 Aug 21. 6506(369).
  
  Model

• Unleashing Immunotherapy by Targeting Cancer Stem Cells.

  Iglesias-Bartolome R, Gutkind JS.
  Cell Stem Cell. 2020 Aug 06. 2(27).

• CoMut: visualizing integrated molecular information with comutation plots.

  Crowdis J, He MX, Reardon B, Van Allen EM.
  Bioinformatics. 2020 Aug 01. 15(36).

• ¹⁷⁷Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer.

  Hernandez R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, Pinchuk AN, Bitton AN, Patel R, Zhang R, Rao AV, Iyer G, Engle JW, Weichert JP.
  J Nucl Med. 2020 Aug. 8(61).

• Old dogs, new trick: classic cancer therapies activate cGAS.

  Yum S, Li M, Chen ZJ.
  Cell Res. 2020 Aug. 8(30).

• Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples.

  Panda A, Yadav A, Yeerna H, Singh A, Biehl M, Lux M, Schulz A, Klecha T, Doniach S, Khiabanian H, Ganesan S, Tamayo P, Bhanot G.
  Nucleic Acids Res. 2020 Jul 27. 13(48).

• The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis.

  Kitamoto S, Nagao-Kitamoto H, Jiao Y, Gillilland MG, Hayashi A, Imai J, Sugihara K, Miyoshi M, Brazil JC, Kuffa P, Hill BD, Rizvi SM, Wen F, Bishu S, Inohara N, Eaton KA, Nusrat A, Lei YL, Giannobile WV, Kamada N.
  Cell. 2020 Jul 23. 2(182).

• A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.

  Castellarin M, Sands C, Da T, Scholler J, Graham K, Buza E, Fraietta JA, Zhao Y, June CH.
  JCI Insight. 2020 Jul 23. 14(5).
  
  Model

• Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway.

  Zhang X, Bai XC, Chen ZJ.
  Immunity. 2020 Jul 14. 1(53).

• A Sectioning and Database Enrichment Approach for Improved Peptide Spectrum Matching in Large, Genome-Guided Protein Sequence Databases.

  Kumar P, Johnson JE, Easterly C, Mehta S, Sajulga R, Nunn B, Jagtap PD, Griffin TJ.
  J Proteome Res. 2020 Jul 02. 7(19).

• Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

  Frigault MJ, Nikiforow S, Mansour MK, Hu ZH, Horowitz MM, Riches ML, Hematti P, Turtle CJ, Zhang MJ, Perales MA, Pasquini MC.
  Blood. 2020 Jul 02. 1(136).

• RBCs prevent rapid PIEZO1 inactivation and expose slow deactivation as a mechanism of dehydrated hereditary stomatocytosis.

  Evans EL, Povstyan OV, De Vecchis D, Macrae F, Lichtenstein L, Futers TS, Parsonage G, Humphreys NE, Adamson A, Kalli AC, Ludlow MJ, Beech DJ.
  Blood. 2020 Jul 02. 1(136).

• Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy.

  Hai J, Zhang H, Zhou J, Wu Z, Chen T, Papadopoulos E, Dowling CM, Pyon V, Pan Y, Liu JB, Bronson RT, Silver H, Lizotte PH, Deng J, Campbell JD, Sholl LM, Ng C, Tsao MS, Thakurdin C, Bass AJ, Wong KK.
  Clin Cancer Res. 2020 Jul 01. 13(26).
  
  Model

• B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.

  Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi AB.
  Clin Cancer Res. 2020 Jul 01. 13(26).

• IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.

  Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenberg MW, Ring AM.
  Nature. 2020 Jul. 7817(583).
  
  Data Model

• Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice.

  Eguchi A, Yan R, Pan SQ, Wu R, Kim J, Chen Y, Ansong C, Smith RD, Tempaku M, Ohno-Machado L, Takei Y, Feldstein AE, Tsukamoto H.
  J Mol Med (Berl). 2020 Jul. 7(98).

• In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.

  Clark PA, Sriramaneni RN, Jin WJ, Jagodinsky JC, Bates AM, Jaquish AA, Anderson BR, Le T, Lubin JA, Chakravarty I, Arthur IS, Heinze CM, Guy EI, Kler J, Klar KA, Carlson PM, Kim KM, Kuo JS, Morris ZS.
  J Immunother Cancer. 2020 Jul. 2(8).

• Cellular sensing of extracellular purine nucleosides triggers an innate IFN-β response.

  Dhanwani R, Takahashi M, Mathews IT, Lenzi C, Romanov A, Watrous JD, Pieters B, Hedrick CC, Benedict CA, Linden J, Nilsson R, Jain M, Sharma S.
  Sci Adv. 2020 Jul. 30(6).
  
  Data

• Detection of response to tumor microenvironment-targeted cellular immunotherapy using nano-radiomics.

  Devkota L, Starosolski Z, Rivas CH, Stupin I, Annapragada A, Ghaghada KB, Parihar R.
  Sci Adv. 2020 Jul. 28(6).

• Intratumoral CD4⁺ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.

  Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L.
  Cell. 2020 Jun 25. 7(181).
  
  Data Clinical Trial

• MUC1-C drives stemness in progression of colitis to colorectal cancer.

  Li W, Zhang N, Jin C, Long MD, Rajabi H, Yasumizu Y, Fushimi A, Yamashita N, Hagiwara M, Zheng R, Wang J, Kui L, Singh H, Kharbanda S, Hu Q, Liu S, Kufe D.
  JCI Insight. 2020 Jun 18. 12(5).
  
  Data

• Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.

  Fucà G, Reppel L, Landoni E, Savoldo B, Dotti G.
  Clin Cancer Res. 2020 Jun 01. 11(26).

• Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.

  Liu C, Sadat SH, Ebisumoto K, Sakai A, Panuganti BA, Ren S, Goto Y, Haft S, Fukusumi T, Ando M, Saito Y, Guo T, Tamayo P, Yeerna H, Kim W, Hubbard J, Sharabi AB, Gutkind JS, Califano JA.
  Clin Cancer Res. 2020 Jun 01. 11(26).

• ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.

  Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW.
  Cancer Res. 2020 Jun 01. 11(80).

• Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.

  Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, Odunsi A.
  J Immunother Cancer. 2020 Jun. 1(8).

• Adoptive T cell therapy: Boosting the immune system to fight cancer.

  Leon E, Ranganathan R, Savoldo B.
  Semin Immunol. 2020 Jun. (49).

• Humoral immune responses: Unsung heroes of the war on cancer.

  Conejo-Garcia JR, Biswas S, Chaurio R.
  Semin Immunol. 2020 Jun. (49).

• IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.

  Ma HY, Yamamoto G, Xu J, Liu X, Karin D, Kim JY, Alexandrov LB, Koyama Y, Nishio T, Benner C, Heinz S, Rosenthal SB, Liang S, Sun M, Karin G, Zhao P, Brodt P, Mckillop IH, Quehenberger O, Dennis E, Saltiel A, Tsukamoto H, Gao B, Karin M, Brenner DA, Kisseleva T.
  J Hepatol. 2020 May. 5(72).

• Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.

  Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L.
  J Immunother Cancer. 2020 May. 1(8).
  
  Clinical Trial

• Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer.

  Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S, Tang DG.
  Nat Commun. 2020 Apr 29. 1(11).
  
  Data

• New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.

  Williams KB, Largaespada DA.
  Genes (Basel). 2020 Apr 28. 5(11).

• Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers.

  Shalapour S, Karin M.
  Annu Rev Immunol. 2020 Apr 26. (38).

• Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.

  Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Villella J, Lugade A, Yao S, Liu S, Moysich K, Odunsi KO.
  Int J Cancer. 2020 Apr 15. 8(146).

• TLR9 Sensing of Self-DNA Controls Cell-Mediated Immunity to Listeria Infection via Rapid Conversion of Conventional CD4⁺ T Cells to T_reg.

  Dolina JS, Lee J, Griswold RQ, Labarta-Bajo L, Kannan S, Greenbaum JA, Bahia El Idrissi N, Pont MJ, Croft M, Schoenberger SP.
  Cell Rep. 2020 Apr 07. 1(31).

• Multi-omics Visualization Platform: An extensible Galaxy plug-in for multi-omics data visualization and exploration.

  McGowan T, Johnson JE, Kumar P, Sajulga R, Mehta S, Jagtap PD, Griffin TJ.
  Gigascience. 2020 Apr 01. 4(9).

• HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING.

  Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, Young S, Wolf GT, Chen Q, Lei YL.
  J Clin Invest. 2020 Apr 01. 4(130).

• Immunotherapy of multiple myeloma.

  Minnie SA, Hill GR.
  J Clin Invest. 2020 Apr 01. 4(130).

• Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.

  Brightman SE, Naradikian MS, Miller AM, Schoenberger SP.
  J Leukoc Biol. 2020 Apr. 4(107).

• Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers.

  Phillips JW, Pan Y, Tsai BL, Xie Z, Demirdjian L, Xiao W, Yang HT, Zhang Y, Lin CH, Cheng D, Hu Q, Liu S, Black DL, Witte ON, Xing Y.
  Proc Natl Acad Sci U S A. 2020 Mar 10. 10(117).
  
  Data

• Immunotherapy, Inflammation and Colorectal Cancer.

  Lichtenstern CR, Ngu RK, Shalapour S, Karin M.
  Cells. 2020 Mar 04. 3(9).

• Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.

  Yang Y, Jain RK, Glenn ST, Xu B, Singh PK, Wei L, Hu Q, Long M, Hutson N, Wang J, Battaglia S, George S.
  J Immunother Cancer. 2020 Mar. 1(8).

• HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.

  Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB.
  Cancer Res. 2020 Feb 15. 4(80).

• Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice.

  Xu J, Ma HY, Liu X, Rosenthal S, Baglieri J, McCubbin R, Sun M, Koyama Y, Geoffroy CG, Saijo K, Shang L, Nishio T, Maricic I, Kreifeldt M, Kusumanchi P, Roberts A, Zheng B, Kumar V, Zengler K, Pizzo DP, Hosseini M, Contet C, Glass CK, Liangpunsakul S, Tsukamoto H, Gao B, Karin M, Brenner DA, Koob GF, Kisseleva T.
  JCI Insight. 2020 Feb 13. 3(5).

• CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.

  Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Bushman FD.
  J Clin Invest. 2020 Feb 03. 2(130).
  
  Data Clinical Trial

• In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma.

  Li F, Huang Q, Luster TA, Hu H, Zhang H, Ng WL, Khodadadi-Jamayran A, Wang W, Chen T, Deng J, Ranieri M, Fang Z, Pyon V, Dowling CM, Bagdatlioglu E, Almonte C, Labbe K, Silver H, Rabin AR, Jani K, Tsirigos A, Papagiannakopoulos T, Hammerman PS, Velcheti V, Freeman GJ, Qi J, Miller G, Wong KK.
  Cancer Discov. 2020 Feb. 2(10).
  
  Data

• Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.

  Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L.
  Cancer Immunol Res. 2020 Feb. 2(8).

• Filmed over with CAR-T cells.

  Adu-Berchie K, Mooney DJ.
  Nat Biomed Eng. 2020 Feb. 2(4).

• Orchestrating single-cell analysis with Bioconductor.

  Amezquita RA, Lun ATL, Becht E, Carey VJ, Carpp LN, Geistlinger L, Marini F, Rue-Albrecht K, Risso D, Soneson C, Waldron L, Pagès H, Smith ML, Huber W, Morgan M, Gottardo R, Hicks SC.
  Nat Methods. 2020 Feb. 2(17).

• Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.

  Detappe A, Mathieu C, Jin C, Agius MP, Diringer MC, Tran VL, Pivot X, Lux F, Tillement O, Kufe D, Ghoroghchian PP.
  Int J Radiat Oncol Biol Phys. 2020 Dec 01. 5(108).

• An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.

  Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ.
  Mol Imaging Biol. 2020 Dec. 6(22).

• Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.

  Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L.
  Cancer Immunol Res. 2020 Dec. 12(8).
  
  Data Clinical Trial

• Engineering cytokines and cytokine circuits.

  Li AW, Lim WA.
  Science. 2020 Nov 27. 6520(370).

• Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window.

  Wang X, Wilhelm J, Li W, Li S, Wang Z, Huang G, Wang J, Tang H, Khorsandi S, Sun Z, Evers B, Gao J.
  Nat Commun. 2020 Nov 17. 1(11).

• Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.

  Li S, Bennett ZT, Sumer BD, Gao J.
  Acc Chem Res. 2020 Nov 17. 11(53).

• Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).

  Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, O'Donnell T, Merritt E, Simons NW, Barcessat V, Del Valle DM, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Laserson U, Rahman A, Kim-Schulze S, Charney AW, Gnjatic S, Gelb BD, Merad M, Bogunovic D.
  Cell. 2020 Nov 12. 4(183).
  
  Data

• Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation.

  Becher LRE, Nevala WK, Sutor SL, Abergel M, Hoffmann MM, Parks CA, Pease LR, Schrum AG, Markovic SN, Gil D.
  Blood Adv. 2020 Nov 10. 21(4).

• Fate and functional roles of Prominin 1⁺ cells in liver injury and cancer.

  Wu R, Pan S, Chen Y, Nakano Y, Li M, Balog S, Tsukamoto H.
  Sci Rep. 2020 Nov 10. 1(10).

• Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.

  Wang H, Najibi AJ, Sobral MC, Seo BR, Lee JY, Wu D, Li AW, Verbeke CS, Mooney DJ.
  Nat Commun. 2020 Nov 10. 1(11).

• Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.

  Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S.
  Blood Adv. 2020 Nov 10. 21(4).

• Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST.

  Chaney KE, Perrino MR, Kershner LJ, Patel AV, Wu J, Choi K, Rizvi TA, Dombi E, Szabo S, Largaespada DA, Ratner N.
  Cancer Res. 2020 Nov 01. 21(80).

• Immune checkpoint inhibitors to treat cutaneous malignancies.

  Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME.
  J Am Acad Dermatol. 2020 Nov. 5(83).

• Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s.

  Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI, Liu S, Ito F.
  Nat Commun. 2020 Oct 27. 1(11).
  
  Data

• Fructose stimulated de novo lipogenesis is promoted by inflammation.

  Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, Ceteci F, Conche C, McNulty R, Shalapour S, Taniguchi K, Meikle PJ, Watrous JD, Moranchel R, Najhawan M, Jain M, Liu X, Kisseleva T, Diaz-Meco MT, Moscat J, Knight R, Greten FR, Lau LF, Metallo CM, Febbraio MA, Karin M.
  Nat Metab. 2020 Oct. 10(2).

• Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model.

  Baniel CC, Sumiec EG, Hank JA, Bates AM, Erbe AK, Pieper AA, Hoefges AG, Patel RB, Rakhmilevich AL, Morris ZS, Sondel PM.
  J Immunother Cancer. 2020 Oct. 2(8).

• An inflammatory cytokine signature predicts COVID-19 severity and survival.

  Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S.
  Nat Med. 2020 Oct. 10(26).
  
  Data

• MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

  Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D.
  Nat Commun. 2020 Jan 17. 1(11).
  
  Data

• CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer.

  Kemnade JO, Elhalawani H, Castro P, Yu J, Lai S, Ittmann M, Mohamed ASR, Lai SY, Fuller CD, Sikora AG, Sandulache VC.
  Sci Rep. 2020 Jan 14. 1(10).

• Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate.

  Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E.
  Clin Cancer Res. 2020 Jan 01. 1(26).

• The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.

  Hou J, Zhang H, Sun B, Karin M.
  J Hepatol. 2020 Jan. 1(72).

• Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

  Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.
  Cancer Discov. 2020 Jan. 1(10).
  
  Clinical Trial

• Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.

  Lu T, Tang J, Shrestha B, Heath BR, Hong L, Lei YL, Ljungman M, Neamati N.
  Theranostics. 2020. 15(10).

• Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma.

  Jin WJ, Erbe AK, Schwarz CN, Jaquish AA, Anderson BR, Sriramaneni RN, Jagodinsky JC, Bates AM, Clark PA, Le T, Lan KH, Chen Y, Kim K, Morris ZS.
  Front Immunol. 2020. (11).

• In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response.

  Baniel CC, Heinze CM, Hoefges A, Sumiec EG, Hank JA, Carlson PM, Jin WJ, Patel RB, Sriramaneni RN, Gillies SD, Erbe AK, Schwarz CN, Pieper AA, Rakhmilevich AL, Sondel PM, Morris ZS.
  Front Immunol. 2020. (11).
  
  Clinical Trial

• Exploiting nanoscale cooperativity for precision medicine.

  Wilhelm J, Wang Z, Sumer BD, Gao J.
  Adv Drug Deliv Rev. 2020. (158).

• Log-epsilon-skew normal: A generalization of the log-normal distribution.

  Hutson AD, Mashtare TL, Mudholkar GS.
  Commun Stat Theory Methods. 2020. 17(49).

• Recapitulation of prostate tissue cell type-specific transcriptomes by an in vivo primary prostate tissue xenograft model.

  Gross NT, Wang J, Fiandalo MV, Cortes Gomez E, Watts A, Godoy AS, Smith GJ, Wu Y.
  PLoS One. 2020. 6(15).

• Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

  Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Lacouture ME.
  Support Care Cancer. 2020 Dec. 12(28).

• Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes.

  Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VB, Senapati D, Kumari S, Liu D, Sboner A, Barbieri CE, Feng F, Billaud JN, Davicioni E, Liu S, Heemers HV.
  Eur Urol Open Sci. 2020 Dec. (22).

• Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.

  Lundh S, Jung IY, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA.
  Clin Exp Med. 2020 Nov. 4(20).

• Immune checkpoint inhibitor-related dermatologic adverse events.

  Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME.
  J Am Acad Dermatol. 2020 Nov. 5(83).

• Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma.

  Heft Neal ME, Bhangale AD, Birkeland AC, McHugh JB, Shuman AG, Rosko AJ, Swiecicki PL, Spector ME, Brenner JC.
  Cancers (Basel). 2020 Oct 22. 11(12).

• Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

  Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M.
  J Am Acad Dermatol. 2020 Oct. 4(83).

• Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers.

  Takahashi H, Oshi M, Asaoka M, Yan L, Endo I, Takabe K.
  Ann Surg Oncol. 2020 Oct. 11(27).

• PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.

  Saglam O, Zhou J, Wang X, Conejo-Garcia JR.
  Int J Gynecol Pathol. 2020 Sep. 5(39).

• Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis.

  Takahashi H, Katsuta E, Yan L, Tokumaru Y, Katz MHG, Takabe K.
  Cancers (Basel). 2020 Jul 24. 8(12).

• Precursor Intensity-Based Label-Free Quantification Software Tools for Proteomic and Multi-Omic Analysis within the Galaxy Platform.

  Mehta S, Easterly CW, Sajulga R, Millikin RJ, Argentini A, Eguinoa I, Martens L, Shortreed MR, Smith LM, McGowan T, Kumar P, Johnson JE, Griffin TJ, Jagtap PD.
  Proteomes. 2020 Jul 08. 3(8).

• Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.

  Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K.
  Oncotarget. 2020 Jul 07. 27(11).

• Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).

  Gruber C, Patel R, Trachman R, Lepow L, Amanat F, Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, Simons N, Barcessat V, Valle DD, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Rahman A, Kim-Schulze S, Charney A, Gnjatic S, Gelb BD, Merad M, Bogunovic D.
  medRxiv. 2020 Jul 06. ().

• Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments.

  Jagodinsky JC, Morris ZS.
  Semin Radiat Oncol. 2020 Apr. 2(30).

• Stearoyl-CoA desaturase and tumorigenesis.

  Kikuchi K, Tsukamoto H.
  Chem Biol Interact. 2020 Jan 25. (316).

• STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.

  Kim JW, Berrios C, Kim M, Schade AE, Adelmant G, Yeerna H, Damato E, Iniguez AB, Florens L, Washburn MP, Stegmaier K, Gray NS, Tamayo P, Gjoerup O, Marto JA, DeCaprio J, Hahn WC.
  Elife. 2020 Jan 08. (9).

• HMMRATAC: a Hidden Markov ModeleR for ATAC-seq.

  Tarbell ED, Liu T.
  Nucleic Acids Res. 2019 Sep 19. 16(47).

• Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.

  Narayanan S, Kawaguchi T, Peng X, Qi Q, Liu S, Yan L, Takabe K.
  Sci Rep. 2019 Sep 17. 1(9).

• Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.

  Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, Van Seventer EE, Tracy A, Wo JY, Carter SL, Willers H, Corcoran RB, Hong TS, Van Allen EM.
  Clin Cancer Res. 2019 Sep 15. 18(25).
  
  Data

• Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.

  Heath BR, Michmerhuizen NL, Donnelly CR, Sansanaphongpricha K, Sun D, Brenner JC, Lei YL.
  J Dent Res. 2019 Sep. 10(98).

• Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.

  Newton JM, Hanoteau A, Liu HC, Gaspero A, Parikh F, Gartrell-Corrado RD, Hart TD, Laoui D, Van Ginderachter JA, Dharmaraj N, Spanos WC, Saenger Y, Young S, Sikora AG.
  J Immunother Cancer. 2019 Aug 13. 1(7).

• Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer.

  Conejo-Garcia JR.
  J Clin Invest. 2019 Jul 29. 9(129).

• Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

  Wu V, Yeerna H, Nohata N, Chiou J, Harismendy O, Raimondi F, Inoue A, Russell RB, Tamayo P, Gutkind JS.
  J Biol Chem. 2019 Jul 19. 29(294).

• Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation.

  Shalapour S, Karin M.
  Immunity. 2019 Jul 16. 1(51).

• Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.

  Burga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CRY, Bollard CM.
  Clin Cancer Res. 2019 Jul 15. 14(25).
  
  Model

• Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

  Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB.
  Clin Cancer Res. 2019 Jul 15. 14(25).

• Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

  Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K.
  J Immunother Cancer. 2019 Jun 20. 1(7).

• TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8⁺ T cell exhaustion.

  Seo H, Chen J, González-Avalos E, Samaniego-Castruita D, Das A, Wang YH, López-Moyado IF, Georges RO, Zhang W, Onodera A, Wu CJ, Lu LF, Hogan PG, Bhandoola A, Rao A.
  Proc Natl Acad Sci U S A. 2019 Jun 18. 25(116).
  
  Data

• Illuminating G-Protein-Coupling Selectivity of GPCRs.

  Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, Ono Y, Shinjo Y, Ishida S, Arang N, Kawakami K, Gutkind JS, Aoki J, Russell RB.
  Cell. 2019 Jun 13. 7(177).

• Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

  Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV.
  Oncogene. 2019 Jun. 23(38).
  
  Data

• Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy.

  Wei L, Hussein AA, Ma Y, Azabdaftari G, Ahmed Y, Wong LP, Hu Q, Luo W, Cranwell VN, Bunch BL, Kozlowski JD, Singh PK, Glenn ST, Smith G, Johnson CS, Liu S, Guru KA.
  J Urol. 2019 Jun. 6(201).

• MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.

  Yamamoto M, Jin C, Hata T, Yasumizu Y, Zhang Y, Hong D, Maeda T, Miyo M, Hiraki M, Suzuki Y, Hinohara K, Rajabi H, Kufe D.
  Cancer Res. 2019 Apr 15. 8(79).

• Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.

  Kumar R, Bhat TA, Walsh EM, Chaudhary AK, O'Malley J, Rhim JS, Wang J, Morrison CD, Attwood K, Bshara W, Mohler JL, Yadav N, Chandra D.
  Cancer Res. 2019 Apr 01. 7(79).

• Deep-learning augmented RNA-seq analysis of transcript splicing.

  Zhang Z, Pan Z, Ying Y, Xie Z, Adhikari S, Phillips J, Carstens RP, Black DL, Wu Y, Xing Y.
  Nat Methods. 2019 Apr. 4(16).
  
  Data

• Early-onset triple-negative breast cancer in multiracial/ethnic populations: Distinct trends of prevalence of truncation mutations.

  Liu Q, Yao S, Zhao H, Hu Q, Kwan ML, Roh JM, Ambrosone CB, Kushi LH, Liu S, Zhu Q.
  Cancer Med. 2019 Apr. 4(8).

• ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

  Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.
  Nat Commun. 2019 Mar 20. 1(10).
  
  Data

• Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study.

  Yao S, Hu Q, Kerns S, Yan L, Onitilo AA, Misleh J, Young K, Lei L, Bautista J, Mohamed M, Mohile SG, Ambrosone CB, Liu S, Janelsins MC.
  Clin Epigenetics. 2019 Mar 12. 1(11).

• Differences in microRNA expression in breast cancer between women of African and European ancestry.

  Gong Z, Wang J, Wang D, Buas MF, Ren X, Freudenheim JL, Belinsky SA, Liu S, Ambrosone CB, Higgins MJ.
  Carcinogenesis. 2019 Mar 12. 1(40).

• Discovery of Allele-Specific Protein-RNA Interactions in Human Transcriptomes.

  Bahrami-Samani E, Xing Y.
  Am J Hum Genet. 2019 Mar 07. 3(104).

• NR4A transcription factors limit CAR T cell function in solid tumours.

  Chen J, López-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A.
  Nature. 2019 Mar. 7749(567).
  
  Data

• Genomic correlates of response to immune checkpoint blockade.

  Keenan TE, Burke KP, Van Allen EM.
  Nat Med. 2019 Mar. 3(25).

• Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells.

  Sharma S, Wang J, Alqassim E, Portwood S, Cortes Gomez E, Maguire O, Basse PH, Wang ES, Segal BH, Baysal BE.
  Genome Biol. 2019 Feb 21. 1(20).
  
  Data

• Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

  Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L.
  Immunity. 2019 Feb 19. 2(50).
  
  Data Model

• Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer.

  Biswas S, Mandal G, Roy Chowdhury S, Purohit S, Payne KK, Anadon C, Gupta A, Swanson P, Yu X, Conejo-Garcia JR, Bhattacharyya A.
  J Immunol. 2019 Dec 15. 12(203).

• Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.

  Voeller J, Erbe AK, Slowinski J, Rasmussen K, Carlson PM, Hoefges A, VandenHeuvel S, Stuckwisch A, Wang X, Gillies SD, Patel RB, Farrel A, Rokita JL, Maris J, Hank JA, Morris ZS, Rakhmilevich AL, Sondel PM.
  J Immunother Cancer. 2019 Dec 06. 1(7).
  
  Clinical Trial

• Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4.

  Wang Z, Wu VH, Allevato MM, Gilardi M, He Y, Luis Callejas-Valera J, Vitale-Cross L, Martin D, Amornphimoltham P, Mcdermott J, Yung BS, Goto Y, Molinolo AA, Sharabi AB, Cohen EEW, Chen Q, Lyons JG, Alexandrov LB, Gutkind JS.
  Nat Commun. 2019 Dec 05. 1(10).
  
  Model

• Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

  Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D.
  Nat Med. 2019 Dec. 12(25).
  
  Data

• Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era.

  Phelan R, Eissa H, Becktell K, Bhatt N, Kudek M, Nuechterlein B, Pommert L, Tanaka R, Baker KS.
  Curr Oncol Rep. 2019 Nov 25. 12(21).

• MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

  Hata T, Rajabi H, Takahashi H, Yasumizu Y, Li W, Jin C, Long MD, Hu Q, Liu S, Fushimi A, Yamashita N, Kui L, Hong D, Yamamoto M, Miyo M, Hiraki M, Maeda T, Suzuki Y, Samur MK, Kufe D.
  Cancer Res. 2019 Nov 15. 22(79).
  
  Data

• Immunity to commensal papillomaviruses protects against skin cancer.

  Strickley JD, Messerschmidt JL, Awad ME, Li T, Hasegawa T, Ha DT, Nabeta HW, Bevins PA, Ngo KH, Asgari MM, Nazarian RM, Neel VA, Jenson AB, Joh J, Demehri S.
  Nature. 2019 Nov. 7783(575).
  
  Data Model

• MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells.

  Rajabi H, Hata T, Li W, Long MD, Hu Q, Liu S, Raina D, Kui L, Yasumizu Y, Hong D, Samur M, Kufe D.
  Oncogene. 2019 Nov. 47(38).
  
  Data

• Preclinical Characterization of ^86/90Y-NM600 in a Variety of Murine and Human Cancer Tumor Models.

  Grudzinski JJ, Hernandez R, Marsh I, Patel RB, Aluicio-Sarduy E, Engle J, Morris Z, Bednarz B, Weichert J.
  J Nucl Med. 2019 Nov. 11(60).

• Defining 'T cell exhaustion'.

  Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, Zehn D.
  Nat Rev Immunol. 2019 Nov. 11(19).

• AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.

  Trillo-Tinoco J, Sierra RA, Mohamed E, Cao Y, de Mingo-Pulido Á, Gilvary DL, Anadon CM, Costich TL, Wei S, Flores ER, Ruffell B, Conejo-Garcia JR, Rodriguez PC.
  Cancer Res. 2019 Oct 01. 19(79).

• Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas.

  Rathe SK, Popescu FE, Johnson JE, Watson AL, Marko TA, Moriarity BS, Ohlfest JR, Largaespada DA.
  Sci Rep. 2019 Jan 23. 1(9).

• Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

  Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD, Saenger YM, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P, Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG.
  J Immunother Cancer. 2019 Jan 15. 1(7).

• Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?

  Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M.
  Cell Metab. 2019 Jan 08. 1(29).
  
  Model

• Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

  Miller AM, Bahmanof M, Zehn D, Cohen EEW, Schoenberger SP.
  Cancer Immunol Res. 2019 Jan. 1(7).

• ⁹⁰Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

  Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP.
  Commun Biol. 2019. (2).

• A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.

  Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB.
  Front Immunol. 2019. (10).

• TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.

  Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L.
  Front Immunol. 2019. (10).

• An Alternative Skew Exponential Power Distribution Formulation.

  Hutson AD.
  Commun Stat Theory Methods. 2019. 12(48).

• A robust Pearson correlation test for a general point null using a surrogate bootstrap distribution.

  Hutson AD.
  PLoS One. 2019. 5(14).

• High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer.

  Katsuta E, Yan L, Takeshita T, McDonald KA, Dasgupta S, Opyrchal M, Takabe K.
  Int J Mol Sci. 2019 Dec 28. 1(21).

• Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.

  Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, Vander Woude AC, Grosse-Perdekamp MT, Dockter T, Tan AD, Beutler A, Loprinzi CL.
  Breast. 2019 Dec. (48).

• The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo.

  Flynn SM, Lesperance J, Macias A, Phanhthilath N, Paul MR, Kim JW, Tamayo P, Zage PE.
  Oncotarget. 2019 Oct 29. 59(10).

• Development of an In Situ Cancer Vaccine via Combinational Radiation and Bacterial-Membrane-Coated Nanoparticles.

  Patel RB, Ye M, Carlson PM, Jaquish A, Zangl L, Ma B, Wang Y, Arthur I, Xie R, Brown RJ, Wang X, Sriramaneni R, Kim K, Gong S, Morris ZS.
  Adv Mater. 2019 Oct. 43(31).

• The empirical likelihood prior applied to bias reduction of general estimating equations.

  Vexler A, Zou L, Hutson AD.
  Comput Stat Data Anal. 2019 Oct. (138).

• Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.

  Kitajima S, Asahina H, Chen T, Guo S, Quiceno LG, Cavanaugh JD, Merlino AA, Tange S, Terai H, Kim JW, Wang X, Zhou S, Xu M, Wang S, Zhu Z, Thai TC, Takahashi C, Wang Y, Neve R, Stinson S, Tamayo P, Watanabe H, Kirschmeier PT, Wong KK, Barbie DA.
  Cancer Cell. 2018 Sep 10. 3(34).

• NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.

  Liu Y, Li Y, Liu S, Adeegbe DO, Christensen CL, Quinn MM, Dries R, Han S, Buczkowski K, Wang X, Chen T, Gao P, Zhang H, Li F, Hammerman PS, Bradner JE, Quayle SN, Wong KK.
  Cancer Res. 2018 Jul 01. 13(78).

• Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.

  Liu S, Li S, Hai J, Wang X, Chen T, Quinn MM, Gao P, Zhang Y, Ji H, Cross DAE, Wong KK.
  Clin Cancer Res. 2018 Jun 01. 11(24).

• Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.

  Osum SH, Coutts AW, Duerre DJ, Tschida BR, Kirstein MN, Fisher J, Bell WR, Delpuech O, Smith PD, Widemann BC, Moertel CL, Largaespada DA, Watson AL.
  Neurooncol Adv. 1(3).

• Immunotherapy Use in Patients With Lung Cancer and Comorbidities.

  von Itzstein MS, Gonugunta AS, Mayo HG, Minna JD, Gerber DE.
  Cancer J. 6(26).